Plasmodium yoelii infection inhibits murine leukaemia WEHI-3 cell proliferation in vivo by promoting immune responses

• Published in: Infectious diseases of poverty 2018-05, Vol.7 (1), p.48-48, Article 48
• Main Authors: Tong, Zhen-Zhen, Fang, Zheng-Ming, Zhang, Qi, Zhan, Yun, Zhang, Yue, Jiang, Wan-Fang, Hou, Xiao, Li, Yong-Long, Wang, Ting
• Format: Article
• Language: English
• Subjects: Anti-leukaemia; Cell proliferation; Leukaemia; Malaria; Mouse leukemia complex; Plasmodium yoelii; WEHI-3 cells
• ISSN: 2049-9957; 2095-5162; 2049-9957
• DOI: 10.1186/s40249-018-0433-4

Leukaemia is a malignant leukocyte disorder with a high fatality rate, and current treatments for this disease are unsatisfactory. Therefore, new therapeutic strategies for leukaemia must be developed. Malaria parasite infection has been shown to be effective at combating certain neoplasms in animal experiments. This study is to demonstrate the anti-leukaemia activity of malaria parasite Plasmodium yoelii (P. yoelii) infection,. In this study, the proportion of CD3, CD19, CD11b and Mac-3 cells was analysed by flow cytometry; the levels of IFN-γ and TNF-α in individual serum samples were measured by enzyme-linked immunosorbent assay, and the phagocytic activity of macrophages and natural killer (NK) cell activity were measured by flow cytometry. We found that P. yoelii infection significantly attenuated the growth of WEHI-3 cells in mice. In addition, tumor cell infiltration into the murine liver and spleen was markedly reduced. We also demonstrated that malaria parasite infection elicited anti-leukaemia activity by promoting immune responses, including increasing the surface markers of T cells (CD3) and B cells (CD19); decreasing the surface markers of monocytes (CD11b) and macrophages (Mac-3); inducing the secretion of IFN-γ and TNF-α; and increasing NK cell and macrophage activity. Malaria parasite infection significantly decreases the number of myeloblasts and inhibits neoplasm proliferation in mice. In addition, malaria parasite infection inhibits murine leukaemia by promoting immune responses.